Bioavailability Study of Leflunomide Tablets Under Fed Conditions

Inclusion Criteria: * Subjects will meet all of the following criteria within 30 days prior to first drug administration(except inclusion #8) * Healthy, surgically sterile (hysterectomy, bilateral oophorectomy) or postmenopausal (for al least 1 year)female subjects, 18 to 65 years of age(inclusive) * Indicate non-child bearing status by one of the following criteria: Indication of successful hysterectomy. No spontaneous menses for al least 1 year, must have luteinizing hormone (LH) and follicle stimulating hormone(FSH) levels within postmenopausal range. Indication of successful bilateral oophorectomy. * Body weight within 20% of the appropriate weight for the subject's height and frame (as published in the 1983 Metropolitan Life Insurance Company Scale, Statistical Bureau) * Negative for: HIV Hepatitis B surface antigen and Hepatitis C antibody Urine tests for drugs of abuse (marijuana, amphetamines, barbiturates, cocaine, opiates, benzodiazepines and methadone). Serum HCG consistent with pregnancy. * No significant disease or clinically significant findings in a physical examination. * No clinically significant findings in vital signs measurements and a 12-lead electrocardiogram(ECG) * Subjects who have received leflunomide within 4 months must have an A77-1726(Metabolite) level below 0.01ug/ml and no subsequent administration of leflunomide since that test. Note: The 30 day screening limit does not apply to this inclusion criterion. * Be informed of the nature of th…